Skip to main content

Becker Muscular Dystrophy

8
Pipeline Programs
8
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Medpace
MedpaceCINCINNATI, OH
3 programs
1
2
SevasemtenPhase 21 trial
Sevasemten 10 mgPhase 21 trial
SevasemtenPhase 11 trial
Active Trials
NCT05160415Completed12Est. Mar 2024
NCT06066580Enrolling By Invitation260Est. Aug 2029
NCT05291091Active Not Recruiting244Est. Sep 2026
Santhera Pharmaceuticals
Santhera PharmaceuticalsSwitzerland - Pratteln
1 program
1
VamorolonePhase 21 trial
Active Trials
NCT05166109Completed46Est. Aug 2025
ReveraGen BioPharma
ReveraGen BioPharmaMD - Rockville
1 program
1
VamorolonePhase 2
Pfizer
PfizerNEW YORK, NY
1 program
1
MYO-029Phase 1/21 trial
Active Trials
NCT00104078Completed108Est. Jan 2007
Biocorp
BiocorpFrance - Issoire
1 program
1
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyPhase 11 trial
Active Trials
NCT04386304Completed22Est. Mar 2022
Epirium Bio
Epirium BioCA - Sacramento
1 program
1
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyPhase 1
Edgewise Therapeutics
4 programs
Defining Endpoints in Becker Muscular DystrophyN/A1 trial
SevasemtenPHASE_1
SevasemtenPHASE_2
Sevasemten 10 mgPHASE_2
Active Trials
NCT05257473Active Not Recruiting80Est. May 2026
Lead Pharma
Lead PharmaNetherlands - Oss
1 program
Evaluation of Limb-Girdle Muscular DystrophyN/A1 trial
Active Trials
NCT00893334CompletedEst. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
MedpaceSevasemten
MedpaceSevasemten 10 mg
Santhera PharmaceuticalsVamorolone
PfizerMYO-029
MedpaceSevasemten
BiocorpSafety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Edgewise TherapeuticsDefining Endpoints in Becker Muscular Dystrophy
Lead PharmaEvaluation of Limb-Girdle Muscular Dystrophy

Clinical Trials (8)

Total enrollment: 772 patients across 8 trials

NCT06066580MedpaceSevasemten

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Start: Nov 2023Est. completion: Aug 2029260 patients
Phase 2Enrolling By Invitation
NCT05291091MedpaceSevasemten 10 mg

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Start: Nov 2022Est. completion: Sep 2026244 patients
Phase 2Active Not Recruiting
NCT05166109Santhera PharmaceuticalsVamorolone

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Start: Jul 2022Est. completion: Aug 202546 patients
Phase 2Completed
NCT00104078PfizerMYO-029

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Start: Feb 2005Est. completion: Jan 2007108 patients
Phase 1/2Completed
NCT05160415MedpaceSevasemten

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

Start: Dec 2021Est. completion: Mar 202412 patients
Phase 1Completed
NCT04386304BiocorpSafety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Start: Jul 2020Est. completion: Mar 202222 patients
Phase 1Completed
NCT05257473Edgewise TherapeuticsDefining Endpoints in Becker Muscular Dystrophy

Defining Endpoints in Becker Muscular Dystrophy

Start: Apr 2022Est. completion: May 202680 patients
N/AActive Not Recruiting
NCT00893334Lead PharmaEvaluation of Limb-Girdle Muscular Dystrophy

Evaluation of Limb-Girdle Muscular Dystrophy

Start: Apr 2009Est. completion: Dec 2013
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.